医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit

2015年05月12日 PM07:56
このエントリーをはてなブックマークに追加


 

TOKYO

HOYA Corporation (TOKYO: 7741) today announced financial results for the fourth quarter and full-year ended March 31, 2015. During the quarter, revenues increased by 10.6% to 127,440 million yen compared with the same period last year. Pre-tax profit for the quarter was 25,309 million yen, while profit for this quarter was 18,513 million yen, both of which marked gains of 27.2% and 45.1%, respectively.

In the Information Technology segment of the HOYA Group, sales of semiconductor- and liquid crystal panel-related products for smartphones and tablet PCs, as well as sales of glass disks for HDDs performed well, but sales of our lineup of digital camera related products continued to perform weakly. In the Life Care segment, sales significantly increased in the eyeglass lens business through stronger sales in overseas markets and inclusion of Seiko Optical Products, a sales company of SEIKO eye wear, as a consolidated subsidiary. The contact lens retail business posted year-on-year sales decline due to the rebound reduction from the last-minute demand in March the previous year before the consumption tax hike. Most of the businesses, excluding the endoscope business, performed quite well. Together with the weaker yen, the revenue posted an increase year-on-year.

For the fiscal year ended March 31, 2015, revenues totaled 489,961 million yen, up 14.6% year on year. Pre-tax profit was 118,249 million yen and profit for the term was 92,941 million yen, an increase of 38.3% and 54.5% respectively year on year.

“Today we announced a new share repurchase program with a maximum of 10 million shares and ¥45 billion. Our policy to allocate resources in M&A opportunities and to use excess cash to reward shareholders continues,” said Hiroshi Suzuki, chief executive officer of HOYA. “Decline in profit for the Life Care segment was mainly due to influence of currency exchange. Sales for eyeglass lens business increased by 20% thanks to healthy growth in Europe and US. I also expect a new intraocular lens product launched this April to become a hit because of its unique and excellent quality.”

HOYA also announced year-end dividends forecast of 45 yen per share. The annual dividends, including the interim dividends of 30 yen per share, will amount to 75 yen per share.

 

Summary of Consolidated Financial Statement

(Millions of Yen: Rounded to the nearest million)                
      Three months ended   Variance   Full year ended   Variance
      Mar./14   Mar./15 (%) Mar./14   Mar./15 (%)
Revenue from all operations 115,224 127,440 10.6 427,575 489,961 14.6
Profit before tax 19,892 25,309 27.2 85,486 118,249 38.3
Profit for the term 12,758 18,513 45.1 60,140 92,941 54.5
Basic earnings per share (yen)   29.46   44.72     135.26   218.23  

*Results are preliminary and unaudited.

 

The full reports are available at http://www.hoya.com

About HOYA

Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company and the leading supplier of innovative high-tech and medical products. Hoya is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, Hoya currently employs a multinational workforce of over 34,000 people. For more information, please visit http://www.hoya.com.

CONTACT

Hoya Group
Akiko Chiba, +81-3-3952-6416
Public Relations
HOYA-pr@hoya.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表